Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 711

1.

Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients.

Herbrink M, Nuijten M, Nuijen B, Huitema ADR, Beijnen JH, Hendriks VM, Blanken P, Janmohamed A, van den Brink W.

J Clin Psychopharmacol. 2018 Jun;38(3):212-217. doi: 10.1097/JCP.0000000000000862.

PMID:
29620701
2.

A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.

Richards C, Iosifescu DV, Mago R, Sarkis E, Reynolds J, Geibel B, Dauphin M.

J Psychopharmacol. 2017 Sep;31(9):1190-1203. doi: 10.1177/0269881117722998. Epub 2017 Aug 31.

3.

Sweet taste liking is associated with subjective response to amphetamine in women but not men.

Weafer J, Lyon N, Hedeker D, de Wit H.

Psychopharmacology (Berl). 2017 Nov;234(21):3185-3194. doi: 10.1007/s00213-017-4702-x. Epub 2017 Jul 31.

PMID:
28762072
4.

Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.

Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M.

JAMA Psychiatry. 2017 Sep 1;74(9):903-910. doi: 10.1001/jamapsychiatry.2017.1889.

5.

Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.

Coghill DR, Banaschewski T, Nagy P, Otero IH, Soutullo C, Yan B, Caballero B, Zuddas A.

CNS Drugs. 2017 Jul;31(7):625-638. doi: 10.1007/s40263-017-0443-y.

6.

Effects of monoaminergic drugs on training-induced motor cortex plasticity in older adults.

Kesar TM, Belagaje SR, Pergami P, Haut MW, Hobbs G, Buetefisch CM.

Brain Res. 2017 Sep 1;1670:106-117. doi: 10.1016/j.brainres.2017.06.015. Epub 2017 Jun 17.

7.

Combined Dextroamphetamine and Transcranial Direct Current Stimulation in Poststroke Aphasia.

Keser Z, Dehgan MW, Shadravan S, Yozbatiran N, Maher LM, Francisco GE.

Am J Phys Med Rehabil. 2017 Oct;96(10 Suppl 1):S141-S145. doi: 10.1097/PHM.0000000000000780.

PMID:
28632508
8.

Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder.

McElroy SL, Hudson JI, Gasior M, Herman BK, Radewonuk J, Wilfley D, Busner J.

Int J Eat Disord. 2017 Aug;50(8):884-892. doi: 10.1002/eat.22722. Epub 2017 May 8.

9.

A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.

Gasior M, Hudson J, Quintero J, Ferreira-Cornwell MC, Radewonuk J, McElroy SL.

J Clin Psychopharmacol. 2017 Jun;37(3):315-322. doi: 10.1097/JCP.0000000000000702.

10.

Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.

Babinski DE, Waxmonsky JG, Waschbusch DA, Humphery H, Pelham WE Jr.

J Child Adolesc Psychopharmacol. 2017 Apr;27(3):250-257. doi: 10.1089/cap.2016.0129. Epub 2016 Dec 19.

PMID:
27991835
11.

Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.

Adler LA, Alperin S, Leon T, Faraone SV.

J Child Adolesc Psychopharmacol. 2017 Mar;27(2):196-199. doi: 10.1089/cap.2016.0121. Epub 2016 Dec 9.

PMID:
27935735
12.

Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence.

Ezard N, Dunlop A, Clifford B, Bruno R, Carr A, Bissaker A, Lintzeris N.

BMC Psychiatry. 2016 Dec 1;16(1):428.

13.

Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.

Richards C, McIntyre RS, Weisler R, Sambunaris A, Brawman-Mintzer O, Gao J, Geibel B, Dauphin M, Madhoo M.

J Affect Disord. 2016 Dec;206:151-160. doi: 10.1016/j.jad.2016.07.006. Epub 2016 Jul 5.

15.

Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.

Guerdjikova AI, Mori N, Blom TJ, Keck PE Jr, Williams SL, Welge JA, McElroy SL.

Hum Psychopharmacol. 2016 Sep;31(5):382-91. doi: 10.1002/hup.2547.

PMID:
27650406
16.

Single-dose effects on the P3no-go ERP component predict clinical response to stimulants in pediatric ADHD.

Ogrim G, Aasen IE, Brunner JF.

Clin Neurophysiol. 2016 Oct;127(10):3277-87. doi: 10.1016/j.clinph.2016.07.011. Epub 2016 Jul 30.

17.

An Investigation of Stimulant Effects on the EEG of Children With Attention-Deficit/Hyperactivity Disorder.

Clarke AR, Barry RJ, Baker IE, McCarthy R, Selikowitz M.

Clin EEG Neurosci. 2017 Jul;48(4):235-242. doi: 10.1177/1550059416664657. Epub 2016 Aug 23.

PMID:
27552823
18.

Investigation of the effects of 'piperazine-containing party pills' and dexamphetamine on interhemispheric communication using electroencephalography.

Lee H, Wang GY, Curley LE, Kydd RR, Kirk IJ, Russell BR.

Psychopharmacology (Berl). 2016 Aug;233(15-16):2869-77. doi: 10.1007/s00213-016-4335-5. Epub 2016 Jun 11.

PMID:
27289365
19.

Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial.

Nuijten M, Blanken P, van de Wetering B, Nuijen B, van den Brink W, Hendriks VM.

Lancet. 2016 May 28;387(10034):2226-34. doi: 10.1016/S0140-6736(16)00205-1. Epub 2016 Mar 22.

PMID:
27015909
20.

Asians compared to Whites show increased response to d-amphetamine on select subjective and cardiovascular measures.

Pang RD, Kirkpatrick MG, Goldenson NI, Guillot CR, Leventhal AM.

Pharmacol Biochem Behav. 2016 May;144:73-7. doi: 10.1016/j.pbb.2016.03.003. Epub 2016 Mar 4.

Supplemental Content

Loading ...
Support Center